Cases of myocarditis and pericarditis have been reported following the receipt of Covid-19 mRNA vaccines. As vaccination campaigns are still to be extended, we aimed to provide a comprehensive assessment of the association, by vaccine and across sex and age groups. Using nationwide hospital discharge and vaccine data, we analysed all 1612 cases of myocarditis and 1613 cases of pericarditis that occurred in France in the period from May 12, 2021 to October 31, 2021. We perform matched case-control studies and find increased risks of myocarditis and pericarditis during the first week following vaccination, and particularly after the second dose, with adjusted odds ratios of myocarditis of 8.1 (95% confidence interval [CI], 6.7 to 9.9) for the BNT162b2 and 30 (95% CI, 21 to 43) for the mRNA-1273 vaccine. The largest associations are observed for myocarditis following mRNA-1273 vaccination in persons aged 18 to 24 years. Estimates of excess cases attributable to vaccination also reveal a substantial burden of both myocarditis and pericarditis across other age groups and in both males and females.

接受 Covid-19 mRNA 疫苗后已有心肌炎和心包炎病例报告。由于疫苗接种活动仍有待扩大，我们的目标是按疫苗、跨性别和年龄组对这种关联进行全面评估。我们利用全国医院出院数据和疫苗数据，分析了 2021 年 5 月 12 日至 2021 年 10 月 31 日期间法国发生的所有 1612 例心肌炎病例和 1613 例心包炎病例。我们进行了匹配的病例对照研究，发现接种疫苗后第一周，特别是第二剂后，心肌炎和心包炎的发生率调整后，BNT162b2 心肌炎的比值比为 8.1（95% 置信区间 [CI]，6.7 至 9.9），而 BNT162b2 的心肌炎调整后比值比为 30（95% CI，21 至 9.9）。 43) mRNA-1273 疫苗。在 18 至 24 岁人群中观察到 mRNA-1273 疫苗接种后心肌炎的最大相关性。对因疫苗接种导致的过量病例的估计也揭示了其他年龄组以及男性和女性心肌炎和心包炎的巨大负担。